Drugs / BNT141
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04683939 | Jan 2022 → Jul 2023 | cholangiocarcinoma, esophageal adenocarcinoma, gastric cancer, gastroesophageal junction adenocarcinoma +2 | BioNTech SE | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BNT141 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04683939 ↗ |
| Modality | Messenger RNA (mRNA) | “A phase 1/2 clinical trial with BNT141 mRNA-LNP has been initiated in advanced CLDN18.2-expressing solid cancers (NCT04683939).” PMID 37860278 ↗ Oct 2023 |
| Route | Intravenous | “Intravenous (IV)” NCT04683939 ↗ |
| Target | CLDN18 | “mediates CLDN18.2-restricted cytotoxicity comparable to IMAB362 recombinant protein” PMID 37860278 ↗ Oct 2023 |